Ceretin 6 Preliminary Results - Revision history

BrianEnigma: Reverted edits by Adamgilcrist (Talk); changed back to last version by Scott

2008-06-05T18:12:56Z

Reverted edits by Adamgilcrist (Talk); changed back to last version by Scott

← Older revision		Revision as of 18:12, 5 June 2008
Line 93:		Line 93:
	compared to group and is marked as an outlier. However, APM data on the blood		compared to group and is marked as an outlier. However, APM data on the blood
	chemistry of HG was inconclusive (see discussion).		chemistry of HG was inconclusive (see discussion).
	~~-----------------------------~~
	~~adamgilcrist~~
	~~Suffering from an addiction. This website has a lot of great resources and treatment centers.~~

	~~http://www.treatmentcenters.org~~

Adamgilcrist: Added comment

2008-06-05T15:02:01Z

Added comment

← Older revision		Revision as of 15:02, 5 June 2008
Line 93:		Line 93:
	compared to group and is marked as an outlier. However, APM data on the blood		compared to group and is marked as an outlier. However, APM data on the blood
	chemistry of HG was inconclusive (see discussion).		chemistry of HG was inconclusive (see discussion).
			-----------------------------
			adamgilcrist
			Suffering from an addiction. This website has a lot of great resources and treatment centers.

			http://www.treatmentcenters.org

Scott at 19:52, 13 March 2007

2007-03-13T19:52:24Z

← Older revision		Revision as of 19:52, 13 March 2007
Line 1:		Line 1:
			{{Season1}}

	<div align=right>J. Cognitive Enhancement</div>		<div align=right>J. Cognitive Enhancement</div>
	==Ceretin takes a leap forward: preliminary results from Ceretin G6 phase 1 testing==		==Ceretin takes a leap forward: preliminary results from Ceretin G6 phase 1 testing==

Scott at 23:02, 2 May 2006

2006-05-02T23:02:17Z

← Older revision		Revision as of 23:02, 2 May 2006
Line 7:		Line 7:

	Preliminary results from Phase 1 testing of the sixth generation of Ceretin demonstrate significant		Preliminary results from Phase 1 testing of the sixth generation of Ceretin demonstrate significant
	improvements over existing broad-spectrum cognitive enhancers. Formation of long-term memories, recall		improvements over existing broad-spectrum cognitive enhancers. Formation of long-term memories, recall and alertness are all enhanced, with performance remaining at a near-constant level during the effective period of the drug. However, issues concerning overdose protection still remain, relating to the conformation of the a2 subunit in C6 Ceretiva.
	and alertness are all enhanced, with performance remaining at a near-constant level during the effective
	period of the drug. However, issues concerning overdose protection still remain, relating to the conformation
	of the a2 subunit in C6 Ceretiva.

	Citation: Rayleigh, A. & Hopkins, E. (268) Nanosecond imaging of Ceretiva interactions in the cortex. J. Cognitive Enhancement 16(38): e52131.		Citation: Rayleigh, A. & Hopkins, E. (268) Nanosecond imaging of Ceretiva interactions in the cortex. J. Cognitive Enhancement 16(38): e52131.

	J. Cognitive Enhancement 1298 April 269 - Volume 17 - Issue 19 - e54137		J. Cognitive Enhancement 1298 April 269 - Volume 17 - Issue 19 - e54137

			---------

	Development of the first generation of Ceretin began in earnest in		Development of the first generation of Ceretin began in earnest in
	255, building on earlier research in alleviating abnormal brain chemistry		255 ''([[Timeline:History\|timeline]])'', building on earlier research in alleviating abnormal brain chemistry
	and function. Improvements in the treatment of narcolepsy,		and function. Improvements in the treatment of narcolepsy,
	aphasia, short term memory impairment and problems with recall and		aphasia, short term memory impairment and problems with recall and
Line 26:		Line 25:
	effective<sup>2</sup>. In 260, Ceretin G1 was released by Cognivia, and Ceretin is		effective<sup>2</sup>. In 260, Ceretin G1 was released by Cognivia, and Ceretin is
	now the world's leading broad-spectrum cognitive enhancer<sup>3</sup>.		now the world's leading broad-spectrum cognitive enhancer<sup>3</sup>.


	Since then, updates to Ceretin have been released regularly, with		Since then, updates to Ceretin have been released regularly, with
Line 37:		Line 37:
	targeting with the aid of functional terahertz nanoscale imaging		targeting with the aid of functional terahertz nanoscale imaging
	(fTNI).		(fTNI).


	In this paper, we describe preliminary results from phase 1 testing of		In this paper, we describe preliminary results from phase 1 testing of
Line 47:		Line 48:
	also an unusual consistent outlier whose below-average performance		also an unusual consistent outlier whose below-average performance
	cannot be accounted for.		cannot be accounted for.


	===Standard dosage testing Methods===		===Standard dosage testing Methods===

	Subjects were 15 male and 15 female volunteers at the joint		Subjects were 15 male and 15 female volunteers at the joint
	PCAG/Cognivia testing facilities in Perplex City. All were graduates		[[PCAG]]/[[Cognivia]] testing facilities in [[Perplex City]]. All were graduates
	over 18 years of age, and gave informed consent to the procedure which		over 18 years of age, and gave informed consent to the procedure which
	was approved by the AUC oversight committee. Serious psychiatric or		was approved by the AUC oversight committee. Serious psychiatric or
Line 71:		Line 73:
	(adaptive, abbreviated v3) while being monitored by magnetoencephalography		(adaptive, abbreviated v3) while being monitored by magnetoencephalography
	(MEG).		(MEG).


	===Results===		===Results===
Line 81:		Line 84:
	40%, with G5 steadily decreasing.		40%, with G5 steadily decreasing.

	'''''Image Forthcoming'''''		<center>'''''Image Forthcoming'''''</center>

	Figure 1 Performance on the WCAS (adaptive, abbreviated v3) intelligence test		Figure 1 Performance on the WCAS (adaptive, abbreviated v3) intelligence test

Scott at 22:40, 2 May 2006

2006-05-02T22:40:16Z

New page

<div align=right>J. Cognitive Enhancement</div>
==Ceretin takes a leap forward: preliminary results from Ceretin G6 phase 1 testing==

[[Alan Rayleigh]], [[Jonas Thomson]], [[Andrew Hodgkin]]

[[Ceretin|Ceretin Division]], [[Cognivia|Cognivia Research]], [[Perplex City]]

Preliminary results from Phase 1 testing of the sixth generation of Ceretin demonstrate significant
improvements over existing broad-spectrum cognitive enhancers. Formation of long-term memories, recall
and alertness are all enhanced, with performance remaining at a near-constant level during the effective
period of the drug. However, issues concerning overdose protection still remain, relating to the conformation
of the a2 subunit in C6 Ceretiva.

Citation: Rayleigh, A. & Hopkins, E. (268) Nanosecond imaging of Ceretiva interactions in the cortex. J. Cognitive Enhancement 16(38): e52131.

J. Cognitive Enhancement 1298 April 269 - Volume 17 - Issue 19 - e54137

Development of the first generation of Ceretin began in earnest in
255, building on earlier research in alleviating abnormal brain chemistry
and function. Improvements in the treatment of narcolepsy,
aphasia, short term memory impairment and problems with recall and
spatial navigation all translated into the realisation that these
treatments could also be used to enhance cognition in normal
individuals1. This team combined the active molecules in the
treatments and synthesised a working drug cocktail that was safe and
effective2. In 260, Ceretin G1 was released by Cognivia, and Ceretin is
now the world's leading broad-spectrum cognitive enhancer3.

Since then, updates to Ceretin have been released regularly, with
Ceretin G5 providing a significant leap forward in performance, resulting
in part from new insights into penetrating the blood-brain barrier
(BBB)4 and harnessing the hypothalamus to alter the state of the
autonomic system5. The main areas we tackled when working on G6
included the drop-off in performance during the effective period and
incompatibilities with ~8% of the population. We also aimed to
incorporate new developments from MNS G36 and improve molecule
targeting with the aid of functional terahertz nanoscale imaging
(fTNI).

In this paper, we describe preliminary results from phase 1 testing of
Ceretin G6. Significant improvements in the performance of G6 over a
24 hour period were evident, in addition to memory and recall.
However, a satisfactory form of overdose protection has yet to be
incorporated; computer simulations indicate an issue with the conformation
of the a2 subunit of the Ceretiva derivative, which may also
cause problems when different forms of Ceretin are mixed. There is
also an unusual consistent outlier whose below-average performance
cannot be accounted for.

===Standard dosage testing Methods===

Subjects were 15 male and 15 female volunteers at the joint
PCAG/Cognivia testing facilities in Perplex City. All were graduates
over 18 years of age, and gave informed consent to the procedure which
was approved by the AUC oversight committee. Serious psychiatric or
medical illness, cognitive enhancer dependence in the last two years or
a history of substance abuse, resulted in exclusion. Mean age was 30.2
years (range 22-37 years). All were tested as genetically compatible
with Ceretin and all had used Ceretin in the past.

Subjects were tested on the WCAS (standardised) with additional
domain-specific modules (see additional resources for more details)
one month prior to drug administration. Comprehensive biometrics
and blood chemistry status were monitored with the APM module
(APM17, Academy Neuroscience Group, Perplex City).
Subjects underwent double-blind oral administration of a standard
dosage of Ceretin G6, Ceretin G5 or a placebo on hour 0. Subjects also
had an fTNI scan prior to administration in order to detect any anomalies.
During the testing, subjects continued to be monitored with the
APM module. Subjects were tested every three hours on the WCAS
(adaptive, abbreviated v3) while being monitored by magnetoencephalography
(MEG).

===Results===

Performance of Ceretin G6 over a 24 hour period as measured by the
WCAS was significantly higher than G5 (figure 1). From hours 0-9,
performance was approximately equal to G5, within the bounds of
error. Beginning from hour 12, results began to diverge with G6
maintaining a performance increase over control of approximately
40%, with G5 steadily decreasing.

'''''Image Forthcoming'''''

Figure 1 Performance on the WCAS (adaptive, abbreviated v3) intelligence test
in the 24 hours after administration, measured against performance of control
subjects. One subject in the C6 group (’HG’) performed significantly poorer
compared to group and is marked as an outlier. However, APM data on the blood
chemistry of HG was inconclusive (see discussion).